Recent 8-K filings for JUNS
Highest-materiality recent filing
Jupiter Neurosciences shareholders approve 4x increase in authorized shares to 500M and new equity plan
- Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
- 2025 Equity Incentive Plan approved, authorizing 5,250,000 shares for future equity awards.
-
Jupiter Neurosciences announces $2M registered direct offering of 7.1M shares at $0.28/share
7,142,858 shares sold at $0.28 per share for gross proceeds of ~$2.0M.
-
Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA
Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
-
Jupiter Neurosciences receives Nasdaq deficiency notices for bid price and market value
Two Nasdaq deficiency notices received Feb 26, 2026: bid price <$1.00 for 30 consecutive days.
-
Jupiter Neurosciences extends payment start on $6M Yorkville convertible notes to April 2026
Omnibus Amendment signed Feb 20, 2026 with Yorkville to revise monthly payment terms.
-
Jupiter Neurosciences draws $1.86M second tranche from Yorkville SEPA; stockholder approval obtained
Second Pre-Paid Advance closing on Dec 23, 2025: $1,860,000 disbursed to Jupiter Neurosciences.
-
Authorized common stock increased from 125M to 500M shares via amendment approved by 20.2M votes for, 4.5M against.
-
Corrects outstanding shares as of October 24, 2025 from 34,833,083 to 34,294,446.
-
Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing
Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.
-
Jupiter Neurosciences regains Nasdaq minimum bid price compliance
Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).
-
Jupiter Neurosciences grants stock options and conditional cash bonuses to executives
Alison Silva granted 255,320 options; Saleem Elmassri granted 102,128 options; exercise price $1.19, 3-yr vest, 10-yr term.
-
Jupiter Neurosciences replaces auditor; prior reports flagged going concern
Assurance Dimensions resigned as auditor effective April 16, 2025 due to discontinuation of PCAOB practice.
-
Jupiter Neurosciences receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified JUNS on Mar 21, 2025 that bid price closed below $1.00 for 30 consecutive business days through Mar 20, 2025.
-
Jupiter Neurosciences revises CFO compensation: monthly fee to Titan increases to $20k for 2025
Monthly fee for CFO services via Titan Advisory Services LLC set at $20,000 for 2025, up from $5,000 during reduction period.
-
One-time payment of $2,300,000 to Dominant Treasure for services to accelerate product development and distribution in Southeast Asia.
-
Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00
IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.
-
Jupiter Neurosciences extends maturity of $1.38M in secured notes by 26 days to Dec 11, 2024
Extended Puritan Note ($1,111,111) and Assigned Note ($266,667) maturity from Nov 15 to Dec 11, 2024.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event other_material